PuSH - Publikationsserver des Helmholtz Zentrums München

Cirac, A. ; Stützle, S. ; Dieckmeyer, M.* ; Adhikary, D. ; Moosmann, A. ; Körber, N. ; Bauer, T. ; Witter, K.* ; Delecluse, H.J.* ; Behrends, U. ; Mautner, J.

Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.

Cancer Immunol. Immunother. 67, 663-674 (2018)
Verlagsversion Postprint DOI PMC
Open Access Gold
The Epstein-Barr virus (EBV) establishes lifelong infections in > 90% of the human population. Although contained as asymptomatic infection by the immune system in most individuals, EBV is associated with the pathogenesis of approximately 1.5% of all cancers in humans. Some of these EBV-associated tumors have been successfully treated by the infusion of virus-specific T-cell lines. Recent sequence analyses of a large number of viral isolates suggested that distinct EBV strains have evolved in different parts of the world. Here, we assessed the impact of such sequence variations on EBV-specific T-cell immunity. With the exceptions of EBNA2 and the EBNA3 family of proteins, an overall low protein sequence disparity of about 1% was noted between Asian viral isolates, including the newly characterized M81 strain, and the prototypic EBV type 1 and type 2 strains. However, when T-cell epitopes including their flanking regions were compared, a substantial proportion was found to be polymorphic in different EBV strains. Importantly, CD4+ and CD8+ T-cell clones specific for viral epitopes from one strain often showed diminished recognition of the corresponding epitopes in other strains. In addition, T-cell recognition of a conserved epitope was affected by amino acid exchanges within the epitope flanking region. Moreover, the CD8+ T-cell response against polymorphic epitopes varied between donors and often ignored antigen variants. These results demonstrate that viral strain heterogeneity may impair antiviral T-cell immunity and suggest that immunotherapeutic approaches against EBV should preferably target broad sets of conserved epitopes including their flanking regions.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.225
0.990
7
8
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter T-cell Therapy ; Epstein-barr Virus ; Strain Variation ; Epitope ; Immunity; Antigen Presentation; Lymphoproliferative Disorders; Clinical-trial; Helper-cells; Recognition; Disease; Diversity; Infection; Therapy; Transplant
Sprache
Veröffentlichungsjahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 0340-7004
e-ISSN 1432-0851
Quellenangaben Band: 67, Heft: 4, Seiten: 663-674 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501500-001
G-502700-002
G-502700-003
Scopus ID 85041134784
PubMed ID 29374782
Erfassungsdatum 2018-01-30